{"id":"azithromycin-iv","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This binding action prevents the translocation of peptides from the A site to the P site on the ribosome, ultimately inhibiting the synthesis of bacterial proteins. As a result, Azithromycin IV exerts its bacteriostatic effects by interfering with the ability of bacteria to produce essential proteins.","oneSentence":"Azithromycin IV is a macrolide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:38.000Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Acute bacterial exacerbation of chronic bronchitis"},{"name":"Acute bacterial sinusitis"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT06396078","phase":"PHASE4","title":"Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-07-18","conditions":"Preterm Premature Rupture of Membrane, Pregnancy, High Risk, Preterm Birth","enrollment":56},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT06077916","phase":"NA","title":"Gastric CLEANsing by Intravenous AZithromycin in Urgent Endoscopy","status":"COMPLETED","sponsor":"Clinical Hospital Colentina","startDate":"2023-10-01","conditions":"Upper Gastrointestinal Bleeding","enrollment":224},{"nctId":"NCT07314281","phase":"PHASE4","title":"Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever","status":"RECRUITING","sponsor":"Indus Hospital and Health Network","startDate":"2025-04-22","conditions":"Enteric Fever","enrollment":40},{"nctId":"NCT06273891","phase":"PHASE3","title":"Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2024-03-08","conditions":"Premature Rupture of Membrane","enrollment":140},{"nctId":"NCT07148622","phase":"NA","title":"Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2024-10-01","conditions":"Preterm Premature Rupture of Membranes (PPROM), Prophylaxis, Perinatal Outcomes","enrollment":40},{"nctId":"NCT05121974","phase":"PHASE2","title":"Tebipenem Trial in Children With Shigellosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-08-18","conditions":"Shigellosis","enrollment":132},{"nctId":"NCT04310930","phase":"PHASE2, PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","enrollment":300},{"nctId":"NCT01556334","phase":"PHASE3","title":"Erythromycin Versus Azithromycin in Preterm Premature Rupture of Membranes","status":"WITHDRAWN","sponsor":"Indiana University","startDate":"2010-04","conditions":"Preterm Premature Ruptured Membranes","enrollment":""},{"nctId":"NCT04390152","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19","status":"TERMINATED","sponsor":"BioXcellerator","startDate":"2020-01-13","conditions":"Acute Respiratory Distress Syndrome","enrollment":6},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT03060473","phase":"PHASE3","title":"Treatment of ppROM With Erythromycin vs. Azithromycin Trial","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2017-02-23","conditions":"Preterm Premature Rupture of Membranes (PPROM)","enrollment":21},{"nctId":"NCT04202380","phase":"NA","title":"Azithromycin for Preterm Pre-labor Rupture of Membranes","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-01-01","conditions":"Preterm Pre-labor Rupture of Membranes","enrollment":300},{"nctId":"NCT05772013","phase":"PHASE4","title":"Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations","status":"RECRUITING","sponsor":"Dr Ian B Wilkinson","startDate":"2024-03-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1311},{"nctId":"NCT04458948","phase":"PHASE2","title":"Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2020-03-24","conditions":"COVID-19","enrollment":28},{"nctId":"NCT05132829","phase":"PHASE4","title":"Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial","status":"UNKNOWN","sponsor":"Thomas Jefferson University","startDate":"2021-12-20","conditions":"Preterm Birth, Obstetric Labor, Premature, Obstetric Labor Complications","enrollment":50},{"nctId":"NCT03854929","phase":"PHASE4","title":"Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2019-12-11","conditions":"Dysentery, Shigella, Shigellosis, Diarrhea","enrollment":364},{"nctId":"NCT05328817","phase":"NA","title":"Azithromycin Versus Erythromycin For Preterm Prelabor Rupture of Membranes","status":"UNKNOWN","sponsor":"Eastern Virginia Medical School","startDate":"2022-05-01","conditions":"Preterm Premature Rupture of Membrane","enrollment":240},{"nctId":"NCT05293977","phase":"NA","title":"Short-Term Use of Antibiotics and Adherence Level","status":"COMPLETED","sponsor":"Jordan University of Science and Technology","startDate":"2020-08-03","conditions":"Acute Infection","enrollment":589},{"nctId":"NCT04353180","phase":"PHASE3","title":"Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2021-08","conditions":"COVID19","enrollment":100000},{"nctId":"NCT04871633","phase":"NA","title":"Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2020-08-01","conditions":"COVID-19","enrollment":66},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04668469","phase":"NA","title":"Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic","status":"COMPLETED","sponsor":"Benha University","startDate":"2020-06-08","conditions":"Covid19","enrollment":600},{"nctId":"NCT04349410","phase":"PHASE2, PHASE3","title":"The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","status":"COMPLETED","sponsor":"The Camelot Foundation","startDate":"2020-04-11","conditions":"CoVid 19 Positive","enrollment":1800},{"nctId":"NCT04361422","phase":"PHASE3","title":"Isotretinoin in Treatment of COVID-19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-12-01","conditions":"COVID-19","enrollment":300},{"nctId":"NCT04395768","phase":"PHASE2","title":"International ALLIANCE Study of Therapies to Prevent Progression of COVID-19","status":"UNKNOWN","sponsor":"National Institute of Integrative Medicine, Australia","startDate":"2020-09-09","conditions":"COVID19","enrollment":200},{"nctId":"NCT02707523","phase":"PHASE2","title":"Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2016-01-01","conditions":"Respiratory Syncytial Virus","enrollment":48},{"nctId":"NCT04395170","phase":"PHASE2, PHASE3","title":"Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.","status":"UNKNOWN","sponsor":"Lifefactors Zona Franca, SAS","startDate":"2020-09","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":75},{"nctId":"NCT04347512","phase":"PHASE3","title":"EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","status":"WITHDRAWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-06-02","conditions":"Sars-CoV-2, Community-Acquired Pneumonia,COVID-19","enrollment":""},{"nctId":"NCT03960970","phase":"PHASE2","title":"Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries","status":"UNKNOWN","sponsor":"RWJ Barnabas Health at Jersey City Medical Center","startDate":"2019-09-15","conditions":"Endometritis, Cesarean Section; Infection, Wound Infection","enrollment":800},{"nctId":"NCT04062175","phase":"PHASE4","title":"Efficacy of Adding Azithromycin to Cephalosporin Before Cesarean Delivery","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-03-20","conditions":"Wound Sepsis","enrollment":144},{"nctId":"NCT00319956","phase":"PHASE2","title":"Trial II of Lung Protection With Azithromycin in the Preterm Infant","status":"COMPLETED","sponsor":"Hubert Ballard","startDate":"2004-09","conditions":"Bronchopulmonary Dysplasia","enrollment":220},{"nctId":"NCT01784770","phase":"","title":"Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-03-27","conditions":"Legionnaires' Disease, Legionella Pneumophila Infections","enrollment":21},{"nctId":"NCT00599053","phase":"PHASE1, PHASE2","title":"Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2007-05","conditions":"Bacteria Infection, Respiratory Tract Infections","enrollment":7},{"nctId":"NCT02115516","phase":"PHASE1","title":"Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2014-04","conditions":"Malaria, Plasmodium Falciparum Malaria","enrollment":67},{"nctId":"NCT01671280","phase":"","title":"Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-09-20","conditions":"Pneumonia, Pelvic Inflammatory Disease","enrollment":403},{"nctId":"NCT00035347","phase":"PHASE4","title":"Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-01","conditions":"Community-Acquired Pneumonia (CAP)","enrollment":219},{"nctId":"NCT01741909","phase":"NA","title":"Reducing Cost of Azythromycin by Transferring From IV to Oral Therapy","status":"WITHDRAWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-12","conditions":"Pneumonia","enrollment":""},{"nctId":"NCT02282176","phase":"PHASE3","title":"TINN2: Treat Infection in NeoNates 2","status":"WITHDRAWN","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2015-01","conditions":"Bronchopulmonary Dysplasia","enrollment":""},{"nctId":"NCT02269644","phase":"PHASE3","title":"A P3 Comparator Trial in Community Acquired Bacterial Pneumonia","status":"WITHDRAWN","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2015-11","conditions":"Community Acquired Pneumonia","enrollment":""},{"nctId":"NCT01820026","phase":"PHASE4","title":"Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2012-12","conditions":"Cirrhosis","enrollment":96},{"nctId":"NCT02380625","phase":"PHASE1, PHASE2","title":"Multiple Treatments for Ebola Virus Disease (EVD)","status":"UNKNOWN","sponsor":"Clinical Research Management, Inc.","startDate":"2015-04","conditions":"Ebola Virus Disease","enrollment":150},{"nctId":"NCT00717561","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-02","conditions":"Pneumonia","enrollment":60},{"nctId":"NCT01431248","phase":"","title":"PPROM Erythromycin Versus Azithromycin","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2011-09","conditions":"Preterm Premature Rupture of Membranes","enrollment":7},{"nctId":"NCT01217099","phase":"NA","title":"Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children","status":"TERMINATED","sponsor":"Chongqing Medical University","startDate":"2007-05","conditions":"Refractory Mycoplasma Pneumoniae Pneumonia","enrollment":47},{"nctId":"NCT00153634","phase":"NA","title":"Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2004-03","conditions":"Cystic Fibrosis, Chronic Bronchitis","enrollment":75},{"nctId":"NCT00610623","phase":"PHASE2","title":"Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia","status":"TERMINATED","sponsor":"Anbics Management-Services Ag","startDate":"2003-04","conditions":"Pneumonia, Ventilator-Associated, Pseudomonas Infections","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zithromac IV"],"phase":"phase_2","status":"active","brandName":"Azithromycin IV","genericName":"Azithromycin IV","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azithromycin IV is a macrolide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit. Used for Community-acquired pneumonia, Acute bacterial exacerbation of chronic bronchitis, Acute bacterial sinusitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}